agilon health inc

AGL remains in a Stage 2 advancing regime with intact higher highs and higher lows, but extreme overbought readings and an exhaustion candle signal limited upside timing edge. Under a speculative mandate, we defer fresh entries and will stalk for pullbacks into the rising 9/20/50 EMA support zone for improved execution.

• ↑Q1 revenue $1.53B beat targets via tech and process upgrades.
• ↑CEO forecasts 2026 profitability gains while investing in platform.
• ↓Q4 medical margin loss $74M and adj. EBITDA -$142M.